Orchid Pharma Ltd

Next 500 2020
+ 6 More
+ 6 More
OVERVIEW
FINANCIALS

About

Orchid Pharma Limited is a Chennai based pharmaceutical company that operates across the value chain. The company specialises in the development, manufacture and distribution of active pharmaceutical ingredients (APIs), bulk actives and nutraceuticals. Orchid’s API product line includes veterinary products, non-antibiotics and oral and injectable cephalosporins among others. The company became a subsidiary of Dhanuka Laboratories Limited in 2020. Orchid is the first Indian company to develop a New Chemical Entity (NCE), essentially a new drug, and secure approval from the U.S. Food and Drug Administration (FDA) for the same. Orchid’s manufacturing facility is one of only three in the world authorized by the USFDA to produce cephalosporins.

Incorporation Year: 1992
Headquarters: Chennai, Tamil Nadu
Top Management: Dhanuka Group; Kailasam Raghavendra Rao
Industry: Pharma

Featured In Fortune India Ranking

Fortune 500 India
#408(2012)
#371(2011)
#289(2010)
#408(2012)#371(2011)#289(2010)
Ranking Trend Fortune 500 India
Next 500 India
#413(2020)#415(2019)#401(2018)#334(2017)
#413(2020)#415(2019)#401(2018)#334(2017)
Ranking Trend Fortune Next 500 India

Financial Data 2024

Revenue
894
(INR Cr)
Net Operating Income
819
(INR Cr)
Assets
1,308
(INR Cr)
Profit
92
(INR Cr)
Net Worth
1,169
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS202420232022202120202019201820172016201520132012201120102009
Revenue
(INR Cr)
894
19.9%
746
14.1%
654
35.6%
482
-8.4%
526
-33.5%
791
13.7%
696
-13.5%
804
-11.1%
905
-52.2%
1893
-5.8%
2011
-2.7%
2066
4.1%
1984
-5.3%
2094
43.9%
1455
-
Net Operating Income
(INR Cr)
819
23.05%
666
19.00%
560
24.33%
450
-6.97%
484
-19.36%
600
-12.15%
683
-14.25%
797
-8.81%
873
-49.99%
1747
-10.32%
1948
3.95%
1874
5.15%
1782
32.63%
1343
3.59%
1297
-0.32%
Profit
(INR Cr)
92
99.0%
46
-
-2
-
-117
-
-131
-
69
-
-353
-
-495
-
-279
-
-197
-
-558
-
97
-37.6%
156
-54.0%
339
-
-49
-
Assets
(INR Cr)
1308
26.7%
1033
11.5%
926
-17.1%
1117
-16.9%
1344
-47.0%
2534
4.8%
2418
-8.6%
2645
-19.0%
3267
-7.8%
3544
-1.3%
3590
14.0%
3148
-1.7%
3203
24.1%
2581
-20.6%
3250
-
Net Worth
(INR Cr)
1169
69.8%
689
6.4%
647
-0.9%
653
-14.8%
766
208.8%
-704
11.1%
-792
-69.6%
-467
-1051.8%
49
-85.1%
329
-13.3%
380
-66.4%
1132
5.9%
1069
14.0%
938
48.0%
634
-4.7%
Employee Cost
(INR Cr)
70
6.6%
65
3.3%
63
-5.7%
67
-10.4%
75
-9.0%
82
-4.6%
86
8.6%
79
-8.5%
87
-55.2%
194
-23.3%
253
43.3%
176
7.1%
165
-5.6%
174
26.9%
137
-
Interest Cost
(INR Cr)
1733335267310347294537523180117242156
Cash & Bank Balance
(INR Cr)
267318201743263062573153912317720133553
Total Debt
(INR Cr)
1353312684535663230320231063215321132042005207916442616

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS202420232022202120202019201820172016201520132012201120102009
Profit As % Of Revenues 10.3%6.2%---8.8%-----4.7%7.9%16.2%-
Profit As % Of Assets 7.1%4.5%---2.7%-----3.1%4.9%13.1%-
Profit As % Of Networth 7.9%6.7%---------8.6%14.6%36.2%-
Interest Cost to EBITDA % 15.1%42.4%61.3%177.7%--1276.3%-248.9%138.2%966.0%65.9%33.9%-91.7%
Debt to Equity Ratio 0.120.480.410.690.74---65.559.758.431.771.941.754.13
RONW 3.0%0.3%---------8.8%15.5%-69.2%-
ROCE 3.2%1.5%-1.1%0.0%0.0%-3.7%0.0%0.0%0.0%0.0%0.0%8.0%10.0%-10.3%0.0%